SCHEMBL7197328

SCHEMBL7197328

CCOC(=O)CC(NC(=O)C(Cl)c1ccc(Cl)cc1)c1cccc(NS(=O)(=O)c2cccc(N)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.41
HIF1A Q16665 2/20 0.40
POLB P06746 2/20 0.39
TP53 P04637 2/20 0.39
THRB P10828 1/20 0.39
PKM P14618 1/20 0.39
MAPT P10636 4/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.38
MAPK1 P28482 1/20 0.38
HTR6 P50406 1/20 0.37
GAA P10253 1/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
ADRB3 P13945 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7191856 0.87 ALDH1A1 (0.52) GPR119HIF1AMAPTALDH1A1L3MBTL1
SCHEMBL7193891 0.87 THRB (0.44) POLBTP53THRBMAPTALDH1A1
SCHEMBL7188012 0.85 POLB (0.47) POLBTP53PKMMAPTALDH1A1
SCHEMBL7194810 0.84 POLB (0.46) POLBTP53PKMMAPTALDH1A1
SCHEMBL7197323 0.83 MAPT (0.44) GPR119HIF1APOLBMAPTALDH1A1
SCHEMBL7196506 0.82 POLB (0.47) POLBTP53THRBMAPTALDH1A1
SCHEMBL3834077 0.81 ALDH1A1 (0.50) POLBTP53PKMMAPTALDH1A1
SCHEMBL7189153 0.81 PKM (0.40) HIF1APOLBTP53THRBPKM
SCHEMBL3809843 0.80 POLB (0.40) POLBTP53THRBPKMMAPT
SCHEMBL7189141 0.79 ALDH1A1 (0.40) HIF1APOLBTP53THRBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6589972-B2 Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects BAYER AKTIENGESELLSCHAFT (DE) 2003-07-08 US disclosed
EP-1147079-A2 BETA-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS Bayer Aktiengesellschaft (DE) 2001-10-24 EP disclosed
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists SCHOOP ANDREAS (DE) 2001-10-18 US disclosed
US-6291503-B1 β-phenylalanine derivatives as integrin antagonists BAYER AKTIENGESELLSCHAFT (DE) 2001-09-18 US disclosed
WO-2000041469-A2 β-PHENYLALANINE DERIVATIVES AS INTEGRIN ANTAGONISTS BAYER AKTIENGESELLSCHAFT (DE) 2000-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010031788-A1 Beta-phenylalanine derivatives as integrin antagonists ITGB4, ITGA4, ITGB2 GPR119 343/4885HIF1A 1204/4885POLB 3274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.